Exciting Advances in Ulcerative Colitis Treatments: Skyrizi Gains Early Momentum Following FDA Approval in June
October 01, 2024 10:51 ET
|
Spherix Global Insights
EXTON, PA, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The past twelve months have been transformative for the rapidly evolving ulcerative colitis (UC) market, with a surge in advanced therapies receiving FDA...
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
October 01, 2024 07:00 ET
|
CytoSorbents
CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor
Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome
September 26, 2024 12:34 ET
|
Minovia Therapeutics
MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria In pre-clinical studies, MNV-201 demonstrated improved...
Global healthcare AI innovator Qure.ai completes $65 million Series D funding round led by Lightspeed and 360One Asset
September 25, 2024 12:00 ET
|
Qure.ai Technologies Limited
Global healthcare AI innovator Qure.ai completes $65 million Series D funding round led by Lightspeed and 360One Asset
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
September 23, 2024 08:17 ET
|
SciSparc Ltd
FDA confirms that SciSparc’s study may proceed following the application submission a month ago TEL AVIV, Israel, Sept. 23, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or...
Kronos Advanced Technologies, Inc. (OTC: KNOS) Announces Ex-Dividend Date for Upcoming Special Cash Dividend
September 16, 2024 03:18 ET
|
Kronos Advanced Technologies Inc.
Los Angeles, CA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Los Angeles, CA September 16, 2024– Kronos Advanced Technologies, Inc. (OTC: KNOS), a leading innovator in advanced air purification technology,...
SS Innovations Conducts Interactive Meeting with the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) and Updates its Expected FDA Approval Timeline
September 11, 2024 08:30 ET
|
SS Innovations
SS Innovations Conducts Interactive Meeting with the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA)
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
September 06, 2024 16:03 ET
|
NurExone Biologic Inc
NurExone demonstrates a longer timeframe of ExoPTEN treatment can be effectively administered post Spinal-Cord Injury
Politicized Medicine Hindered Use of Ivermectin for COVID, according to the Journal of American Physicians and Surgeons
September 04, 2024 11:12 ET
|
Association of American Physicians and Surgeons
The politicized response to Covid included a war on the use of ivermectin. Studies have conflicting results. The issue is at a stalemate.
Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)
September 03, 2024 09:00 ET
|
Longeveron
Longeveron announces positive Type C meeting with FDA, clarifying regulatory pathway to BLA submission for Lomecel-B for hypoplastic left heart syndrome.